1. Home
  2. Press release
Mar 26, 2018 13:36 JST

Source: Hitachi, Ltd.

Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology
to Begin Collaborative Creation for Improving Efficiency of Clinical Trials
for New Drug Development

Aiming to shorten the period of clinical trial and reduce development cost, and improve the probability of successful new drug development

TOKYO, Mar 26, 2018 - (JCN Newswire) - Mitsubishi Tanabe Pharma Corporation (TSE: 4508) and Hitachi, Ltd. (TSE: 6501) today announced that they have initiated collaborative creation for improving the efficiency of clinical trials for the development of new drugs. The companies undertake a wide range of operations to make clinical trials more efficient overall, using Hitachi's advanced digital technology such as AI(1), aiming to shorten the period for development of new drugs and reduce development cost, while improving the probability of successful development.

The business environment surrounding pharmaceutical companies in Japan is expected to become increasingly severe given the lowering of drug prices and the substantial increase of the market share of generics. For the business to achieve continued growth, a review of the process for the fast development of new drugs that satisfy unmet medical needs(2) is required. In particular, clinical trials in which new drugs are administered to humans for evaluating efficacy and safety as well as possible side-effects are an important process for the successful development of new drugs. However, since the elaborate design of a trial plan is needed, a huge amount of time and the know-how as well as the experience of skilled experts are necessary.

To meet these challenges, Mitsubishi Tanabe Pharma and Hitachi focused on the fact that a lot of time is spent searching and collecting information from technical knowledge in medicine such as medical papers and ClinicalTrials.gov(3) in the planning stage of clinical trials, and the two companies began considering automated information search and collection jointly at the beginning of 2017. By utilizing AI technology such as natural language processing and deep learning(4), which the Research & Development Group of Hitachi has developed for medical use, the companies have confirmed that the time spent collecting information is shortened by about 70% when compared with conventional operations, which depend on the know-how of skilled experts, while the accuracy of the data collected and organized is also verified, so that the companies have obtained a perspective on the feasibility of full-scale use.

Mitsubishi Tanabe Pharma and Hitachi have initiated collaborative creation for making a wide range of operations related to the entire clinical trial process more efficient. Mitsubishi Tanabe Pharma, with a corporate philosophy of that "We contribute to the healthier lives of people around the world through the creation of pharmaceuticals," has long been involved in the research and development of pharmaceuticals, having an advantage in its extensive medical knowledge and wide ranging capabilities for drug discovery. Meanwhile, Hitachi utilizes the knowledge and experience that it has accumulated as a manufacturer over many years, and the digital solution created by its IoT platform "Lumada," undertaking the social innovation business to provide solutions to the issues of its clients. The two companies use their technology and know-how, collaboratively working on improving the efficiency of clinical trials by using an array of advanced digital technologies, including AI. In addition, the companies plan to expand the scope of their collaborative creation in the future to undertake a wide range of demonstration experiments.

As a first step, Hitachi will roll out a solution of automated technology for collection of information from medical literature to the pharmaceutical industry in Japan and overseas starting in 2018. This automated solution will be developed through collaborative creation with utilization of Hitachi's IoT platform, "Lumada."

(1) AI: Artificial Intelligence
(2) Unmet medical needs: medical needs for disease, for which no effective treatment is available.
(3) ClinicalTrials.gov: Database that provides information on ongoing clinical trials and clinical research through the US National Library of Medicine(NLM), which is jointly run by the National Institute of Health(NIH) and the Food and Drug Administration(FDA) in the United States.
(4) Deep learning: Machine learning method using a multi-layer deep neural network.

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation is a research-driven pharmaceutical company based in Osaka Japan. Mitsubishi Tanabe Pharma is taking on the challenge of drug discovery in the fields of autoimmune disorders, central nervous system diseases, diabetes and kidney diseases, and vaccines. To those ends, the Company is strengthening its R&D pipeline. Mitsubishi Tanabe Pharma contributes to the healthier lives of people around the world through the creation of pharmaceuticals. https://www.mt-pharma.co.jp/e.

Contact:
Hitachi Ltd
Corporate Communications
Tel: +81-3-3258-1111
Source: Hitachi, Ltd.
Sectors: Electronics, Enterprise IT, BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Hitachi Energy acquires remaining stake of eks Energy, reinforcing leadership in power conversion systems for energy storage
August 29 2025 14:17 JST
 
Hitachi High-Tech and NOF Metal Coatings use materials informatics to improve the efficiency and sophistication of research and development work
August 19 2025 15:38 JST
 
Hitachi completes capital reorganization of air conditioning joint venture accelerating the deployment of green cooling solutions through "One Hitachi"
August 01 2025 18:00 JST
 
Prototype divertor outer vertical target for the ITER fusion experimental reactor is completed and the sample has passed the ITER Organization's certification test
July 23 2025 12:10 JST
 
Hitachi, global investment firm Brookfield, and global commodities trading firm Hartree Begin to Explore a Funding Scheme in the Environmentally-friendly Digital Infrastructure Sector
July 17 2025 13:16 JST
 
All Nippon Airways and Hitachi Unveil Japan's First Airline "Operations Brain" System, Enabling Rapid, Optimal Flight Schedule Revisions During Disruptions
July 15 2025 11:00 JST
 
Hitachi develops "Metaverse Platform for Nuclear Power Plants" to enhance efficiency in construction and maintenance operations
July 09 2025 18:02 JST
 
Hitachi Industrial Equipment Systems Launches Next-Generation Inverter System to Support Stable, Resilient Power Grids
April 18 2025 15:46 JST
 
Kirin and Hitachi begin joint research on the creation of forest-based carbon credits
April 04 2025 14:56 JST
 
Hitachi's New Corporate Vision: Changing the World and Future with the Power of Knowledge
April 01 2025 17:46 JST
 
More Press release >>

Latest Press Release


Hong Kong Watch & Clock Fair, Salon de TIME return in September
Aug 30, 2025 02:50 JST

Honda Announces New Plan for Relocation of Global Head Office to Yaesu Area in Tokyo and Reconstruction of Honda Aoyama Building
Aug 29, 2025 18:54 JST

Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 29, 2025 18:17 JST

Hitachi Energy acquires remaining stake of eks Energy, reinforcing leadership in power conversion systems for energy storage
Aug 29, 2025 15:17 JST

SenseTime Announces 2025 Interim Results
Aug 28, 2025 21:20 JST

Ausnutria 2025 Interim Results Announcement: Revenue and Profit Maintain Resilient Dual Growth
Aug 28, 2025 19:09 JST

Baguio Green Group (1397.HK) Announces 2025 Interim Results
Aug 28, 2025 19:03 JST

Production, Sales and Export Results for July, 2025
Aug 28, 2025 17:36 JST

Sales, Production, and Export Results for July 2025
Aug 28, 2025 17:25 JST

The University of Tokyo and DENSO Jointly Establish a Social Cooperation Program: "Building Sustainable Production System Infrastructure with Advanced AI Technology"
Aug 28, 2025 16:33 JST

Overview of Honda Exhibits at the Japan Mobility Show 2025
Aug 28, 2025 15:49 JST

NEC develops AI technology for digitalizing work tasks without the need for pre-training and utilizing video from multiple cameras covering wide area worksites
Aug 27, 2025 22:57 JST

Result of the Business Plan Review for the Offshore Wind Power Generation Projects in Japan
Aug 27, 2025 22:27 JST

Fujitsu develops AI agent platform for the healthcare sector to enhance operational efficiency and ensure stable medical service provision
Aug 27, 2025 21:50 JST

MHI Becomes First Japanese Company to Acquire ISO 19443:2018 Certification in the Nuclear Energy Field
Aug 27, 2025 21:32 JST

Mitsubishi Logisnext to Demonstrate Automated Forklift Equipped with "SynfoX" at "4th INNOVATION EXPO"
Aug 27, 2025 20:59 JST

TANAKA to Showcase Advanced Semiconductor Materials in its Inaugural Participation at SEMICON India 2025
Aug 26, 2025 13:30 JST

Honda to Hold Official e-Motorsports Event, "Honda Racing eMS 2025"
Aug 26, 2025 13:17 JST

Mitsubishi Corporation Invests in Fullerton Health
Aug 26, 2025 12:54 JST

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 25, 2025 19:30 JST
 More Latest Release >>